Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 12/2017

01-12-2017 | Original Research Article

Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women

Authors: André Dallmann, Ibrahim Ince, Juri Solodenko, Michaela Meyer, Stefan Willmann, Thomas Eissing, Georg Hempel

Published in: Clinical Pharmacokinetics | Issue 12/2017

Login to get access

Abstract

Background

Since pregnant women are considerably underrepresented in clinical trials, information on optimal dosing in pregnancy is widely lacking. Physiologically based pharmacokinetic (PBPK) modeling may provide a method for predicting pharmacokinetic changes in pregnancy to guide subsequent in vivo pharmacokinetic trials in pregnant women, minimizing associated risks.

Objectives

The goal of this study was to build and verify a population PBPK model that predicts the maternal pharmacokinetics of three predominantly renally cleared drugs (namely cefazolin, cefuroxime, and cefradine) at different stages of pregnancy. It was further evaluated whether the fraction unbound (f u) could be estimated in pregnant women using a proposed scaling approach.

Methods

Based on a recent literature review on anatomical and physiological changes during pregnancy, a pregnancy population PBPK model was built using the software PK-Sim®/MoBi®. This model comprised 27 compartments, including nine pregnancy-specific compartments. The PBPK model was verified by comparing the predicted maternal pharmacokinetics of cefazolin, cefuroxime, and cefradine with observed in vivo data taken from the literature. The proposed scaling approach for estimating the f u in pregnancy was evaluated by comparing the predicted f u with experimentally observed f u values of 32 drugs taken from the literature.

Results

The pregnancy population PBPK model successfully predicted the pharmacokinetics of cefazolin, cefuroxime, and cefradine at all tested stages of pregnancy. All predicted plasma concentrations fell within a 2-fold error range and 85% of the predicted concentrations within a 1.25-fold error range. The f u in pregnancy could be adequately predicted using the proposed scaling approach, although a slight underestimation was evident in case of drugs bound to α1-acidic glycoprotein.

Conclusion

Pregnancy population PBPK models can provide a valuable tool to predict a priori the pharmacokinetics of predominantly renally cleared drugs in pregnant women. These models can ultimately support informed decision making regarding optimal dosing regimens in this vulnerable special population
Appendix
Available only for authorised users
Literature
1.
Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205(1):51.e1–8.CrossRef
2.
Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby A-C, Moretti ME, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365.PubMedPubMedCentralCrossRef
3.
Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women’s Hospital. Int J Pharm Pract. 2010;18(4):226–9.PubMed
4.
5.
Tasnif Y, Morado J, Hebert MF. Pregnancy-related pharmacokinetic changes. Clin Pharmacol Ther. 2016;100(1):53–62.PubMedCrossRef
6.
Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013;41(2):256–62.PubMedPubMedCentralCrossRef
7.
Hebert MF. Impact of pregnancy on maternal pharmacokinetics of medications. In: Mattison DR, editor. Clinical pharmacology during pregnancy, 1st ed. Waltham: Academic Press, Elsevier Inc.; 2013. p. 17–39.
8.
9.
Foulkes MA, Grady C, Spong CY, Bates A, Clayton JA. Clinical research enrolling pregnant women: a workshop summary. J Womens Health (Larchmt). 2011;20(10):1429–32.PubMedCentralCrossRef
10.
11.
12.
Ayad M, Costantine MM, editors. Epidemiology of medications use in pregnancy. Semin Perinatol. 2015;39:508–11.
13.
Faden R, Lyerly A, Little M. A custom drug. New York Times; 2009. p. WK10.
14.
Luecke RH, Wosilait WD, Pearce BA, Young JF. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology. 1994;49(2):90–103.PubMedCrossRef
15.
Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol. 2012;74(5):873–85.PubMedPubMedCentralCrossRef
16.
Ke A, Nallani S, Zhao P, Rostami-Hodjegan A, Unadkat JD. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. CPT Pharmacomet Syst Pharmacol. 2012;1(9):1–10.CrossRef
17.
Xia B, Heimbach T, Gollen R, Nanavati C, He H. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J. 2013;15(4):1012–24.PubMedPubMedCentralCrossRef
18.
Wagner C, Zhao P, Pan Y, Hsu V, Grillo J, Huang S, et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT Pharmacomet Syst Pharmacol. 2015;4(4):226–30.CrossRef
19.
Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin pharmacokinet. 2017. doi:10.​1007/​s40262-017-0539-z.
20.
Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011;2(4):1–10.
21.
PK-Sim user manual and software, 6.3. Leverkusen, Germany: Bayer Technology Services GmbH; 2016.
22.
Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401–31.PubMedCrossRef
23.
Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’model. Biosilico. 2003;1(4):121–4.CrossRef
24.
25.
Nightingale CH, Greene DS, Quintiliani R. Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci. 1975;64(12):1899–927.PubMedCrossRef
26.
Ueo H, Motohashi H, Katsura T, Inui KI. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005;70(7):1104–13.PubMedCrossRef
27.
Uwai Y, Saito H, Inui KI. Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone. Drug Metab Pharmacokinet. 2002;17(2):125–9.PubMedCrossRef
28.
Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol. 2007;71(6):1591–7.PubMedCrossRef
29.
Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet. 1987;12(2):136–44.PubMedCrossRef
30.
Fahey JO. Clinical management of intra-amniotic infection and chorioamnionitis: a review of the literature. J Midwifery Womens Health. 2008;53(3):227–35.PubMedCrossRef
31.
32.
33.
Garton A, Rennie R, Gilpin J, Marrelli M, Shafran S. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. J Antimicrob Chemother. 1997;40(6):903–6.PubMedCrossRef
34.
Verhagen C, Mattie H, Strijen E. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol. 1994;37(2):193–7.PubMedPubMedCentralCrossRef
35.
Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol. 1982;142(7):823–8.PubMedCrossRef
36.
Bousfield P, Browning A, Mullinger B, Elstein M. Cefuroxime: potential use in pregnant women at term. Br J Obstet Gynaecol. 1981;88(2):146–9.PubMedCrossRef
37.
Ugwumadu A. Managing bacterial infections in pregnancy and the puerperium. Prescriber. 2010;21(21):53–7.CrossRef
38.
Rattie ES, Bernardo PD, Ravin LJ. Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in humans. Antimicrob Agents Chemother. 1976;10(2):283–7.PubMedPubMedCentralCrossRef
39.
Neiss ES. Cephradine—a summary of preclinical studies and clinical pharmacology. J Ir Med Assoc. 1973;Suppl.:1–12.
40.
Mischler TW, Sugerman AA, Willard DA, Brannick LJ, Neiss ES. Influence of probenecid and food on the bioavailability of cephradine in normal male subjects. J Clin Pharmacol. 1974;14(11):604–11.PubMedCrossRef
41.
Cihlar T, Ho ES. Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000;283(1):49–55.PubMedCrossRef
42.
Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui KI. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem Pharmacol. 2007;74(2):359–71.PubMedCrossRef
43.
Zappala AF, Holl WW, Post A. Cefazolin. In: Florey K, editor. Analytical profiles of drug substances. New York: Academic Press; 1975. p. 1–20.
44.
45.
Gulyaeva N, Zaslavsky A, Lechner P, Chait A, Zaslavsky B. Relative hydrophobicity of organic compounds measured by partitioning in aqueous two-phase systems. J Chromatogr B Biomed Sci Appl. 2000;743(1):187–94.PubMedCrossRef
46.
Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–83.PubMedPubMedCentralCrossRef
47.
Yamana T, Tsuji A. Comparative stability of cephalosporins in aqueous solution: kinetics and mechanisms of degradation. J Pharm Sci. 1976;65(11):1563–74.PubMedCrossRef
48.
Karalis V, Tsantili-Kakoulidou A, Macheras P. Quantitative structure–pharmacokinetic relationships for disposition parameters of cephalosporins. Eur J Pharm Sci. 2003;20(1):115–23.PubMedCrossRef
49.
Park E-S, Maniar M, Shah JC. Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: preparation, and kinetics and mechanism of in vitro release. J Control Release. 1998;52(1):179–89.PubMedCrossRef
50.
51.
Yalkowsky SH, Dannenfelser RM. Aquasol database of aqueous solubility. Tucson: College of Pharmacy, University of Arizona; 1992.
52.
Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci. 2001;90(4):436–47.PubMedCrossRef
53.
Poulin P, Theil FP. A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci. 2000;89(1):16–35.PubMedCrossRef
54.
Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2008;22(2):457–67.PubMedCrossRef
55.
Arayne MS, Sultana N, Afzal M. Cephradine antacids interaction studies. Pak J Pharm Sci. 2007;20(3):179–84.PubMed
56.
Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.PubMedCrossRef
57.
Mrestani Y, Mrestani-Klaus C, Bretschneider B, Neubert RH. Improvement of lipophilicity and membrane transport of cefuroxime using in vitro models. Eur J Pharm Biopharm. 2004;58(3):653–7.PubMedCrossRef
58.
Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem. 2004;47(16):4022–31.PubMedCrossRef
59.
Sloop CH, Dory L, Roheim PS. Interstitial fluid lipoproteins. J Lipid Res. 1987;28(3):225–37.PubMed
60.
Castellucci M, Kaufmann P. A three-dimensional study of the normal human placental villous core: II. Stromal architecture. Placenta. 1982;3(3):269–85.PubMedCrossRef
61.
Jones C, Harris L, Whittingham J, Aplin J, Mayhew T. A re-appraisal of the morphophenotype and basal lamina coverage of cytotrophoblasts in human term placenta. Placenta. 2008;29(2):215–9.PubMedCrossRef
62.
Meuldermans W, Hurkmans R, Heykants J. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther. 1982;257(1):4–19.PubMed
63.
Meuldermans W, Woestenborghs R, Noorduin H, Camu F, van Steenberge A, Heykants J. Protein binding of the analgesics alfentanil and sufentanil in maternal and neonatal plasma. Eur J Clin Pharmacol. 1986;30(2):217–9.PubMedCrossRef
64.
Herngren L, Ehrnebo M, Boreus L. Drug binding to plasma proteins during human pregnancy and in the perinatal period. Studies on cloxacillin and alprenolol. Dev Pharmacol Ther. 1983;6(2):110–24.PubMedCrossRef
65.
Crawford JS, Hooi HW. Binding of bromsulphthalein by serum albumin from pregnant women, neonates and subjects on oral contraceptives. Br J Anaesth. 1968;40(10):723–9.PubMedCrossRef
66.
Wulf H, Münstedt P, Maier C. Plasma protein binding of bupivacaine in pregnant women at term. Acta Anaesthesiol Scand. 1991;35(2):129–33.PubMedCrossRef
67.
Zhang F, Xue J, Shao J, Jia L. Compilation of 222 drugs’ plasma protein binding data and guidance for study designs. Drug Discov Today. 2012;17(9):475–85.PubMedCrossRef
68.
Bardy A, Hiilesmaa V, Teramo K, Neuvonen P. Protein binding of antiepileptic drugs during pregnancy, labor, and puerperium. Ther Drug Monit. 1990;12(1):40–6.PubMedCrossRef
69.
Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36(7):1385–405.PubMedCrossRef
70.
Bourget P, Fernandez H, Quinquis V, Delouis C. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. Antimicrob Agents Chemother. 1993;37(1):54–9.PubMedPubMedCentralCrossRef
71.
Crauwels H, Kakuda T, Ryan B, Zorrilla C, Osiyemi O, Yasin S, et al. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1–infected pregnant women. HIV Med. 2016;17:643–52.PubMedCrossRef
72.
Tsuei SE, Petersen MC, Ashley JJ, McBride WG, Moore RG. Disporition of synthetic glucocorticoids. II. Dexamethasone in parturient women. Clin Pharmacol Ther. 1980;28(1):88–98.PubMedCrossRef
73.
Osathanondh R, Tulchinsky D, Kamali H, deM Fencl M, Taeusch HW. Dexamethasone levels in treated pregnant women and newborn infants. J Pediatr. 1977;90(4):617–20.PubMedCrossRef
74.
75.
Wood M, Wood AJ. Changes in plasma drug binding and α1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther. 1981;29(4):522–6.PubMedCrossRef
76.
Ridd MJ, Brown KF, Nation RL, Collier CB. The disposition and placental transfer of diazepam in cesarean section. Clin Pharmacol Ther. 1989;45(5):506–12.PubMedCrossRef
77.
Hebert M, Easterling T, Kirby B, Carr D, Buchanan M, Rutherford T, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington Specialized Center of Research Study. Clin Pharmacol Ther. 2008;84(2):248–53.PubMedCrossRef
78.
Kim J. Pharmacokinetics and pharmacodynamics of the selective serotonin reuptake inhibitors, fluoxetine and paroxetine, during pregnancy and the nursing period. Vancouver: University of British Columbia; 2000.
79.
Cutler RE, Blair AD. Clinical pharmacokinetics of frusemide. Clin Pharmacokinet. 1979;4(4):279–96.PubMedCrossRef
80.
Riva E, Farina P, Tognoni G, Bottino S, Orrico C, Pardi G. Pharmacokinetics of furosemide in gestosis of pregnancy. Eur J Clin Pharmacol. 1978;14(5):361–6.PubMedCrossRef
81.
Aweeka F, Stek A, Best B, Hu C, Holland D, Hermes A, et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010;11(4):232–8.PubMedCrossRef
82.
Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985;233(1):1–6.PubMed
83.
Högstedt S, Lindberg B, Peng DR, Regårdh CG, Rane A. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther. 1985;37(6):688–92.PubMedCrossRef
84.
Asali L, Brown K. Naloxone protein binding in adult and foetal plasma. Eur J Clin Pharmacol. 1984;27(4):459–63.PubMedCrossRef
85.
Mazoit JX, Samii K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol. 1999;47(1):35–42.PubMedPubMedCentralCrossRef
86.
Gin T, Yau G, Jong W, Tan P, Leung R, Chan K. Disposition of propofol at caesarean section and in the postpartum period. Br J Anaesth. 1991;67(1):49–53.PubMedCrossRef
87.
Lalonde RL, Tenero DM, Burlew BS, Herring VL, Bottorff MB. Effects of age on the protein binding and disposition of propranolol stereoisomers. Clin Pharmacol Ther. 1990;47(4):447–55.PubMedCrossRef
88.
Belpaire F, Wynant P, Trappen P, Dhont M, Verstraete A, Bogaert M. Protein binding of propranolol and verapamil enantiomers in maternal and foetal serum. Br J Clin Pharmacol. 1995;39(2):190–3.PubMedPubMedCentralCrossRef
89.
Morton C, Bloomfield S, Magnusson A, Jozwiak H, McClure J. Ropivacaine 0.75% for extradural anaesthesia in elective caesarean section: an open clinical and pharmacokinetic study in mother and neonate. Br J Anaesth. 1997;79(1):3–8.PubMedCrossRef
90.
Crawford JS, Hooi HW. Binding of salicylic acid and sulphanilamide in serum from pregnant patients, cord blood and subjects taking oral contraceptives. Br J Anaesth. 1968;40(11):825–33.PubMedCrossRef
91.
Gardner M, Schatz M, Cousins L, Zeiger R, Middleton E, Jusko W. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur J Clin Pharmacol. 1987;32(3):289–95.PubMedCrossRef
92.
Connelly TJ, Ruo TI, Frederiksen MC, Atkinson AJ. Characterization of theophylline binding to serum proteins in pregnant and nonpregnant women. Clin Pharmacol Ther. 1990;47(1):68–72.PubMedCrossRef
93.
Gross AS, Heuer B, Eichelbaum M. Stereoselective protein binding of verapamil enantiomers. Biochem Pharmacol. 1988;37(24):4623–7.PubMedCrossRef
94.
Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bull World Health Organ. 1987;65(5):663–737.PubMedPubMedCentral
95.
Wu G, Baraldo M, Furlanut M. Calculating percentage prediction error: a user’s note. Pharmacol Res. 1995;32(4):241–8.PubMedCrossRef
96.
De Sousa Mendes M, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015;80(5):1031–41.CrossRef
97.
Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy. Clin Pharmacokinet. 2012;51(6):365–96.PubMedCrossRef
98.
Christensen T, Klebe JG, Bertelsen V, Hansen HE. Changes in renal volume during normal pregnancy. Acta Obstet Gynecol Scand. 1989;68(6):541–3.PubMedCrossRef
99.
Cietak K, Newton J. Serial qualitative maternal nephrosonography in pregnancy. Br J Radiol. 1985;58(689):399–404.PubMedCrossRef
100.
Farrell D, Morrissey I, De Rubeis D, Robbins M, Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect. 2003;46(2):94–100.PubMedCrossRef
101.
Chitty LS, Altman DG. Charts of fetal size: kidney and renal pelvis measurements. Prenat Diagn. 2003;23(11):891–7.PubMedCrossRef
102.
Arant BS. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978;92(5):705–12.PubMedCrossRef
103.
Verner M-A, Ayotte P, Muckle G, Charbonneau M, Haddad S. A physiologically based pharmacokinetic model for the assessment of infant exposure to persistent organic pollutants in epidemiologic studies. Environ Health Persp. 2009;117(3):481.CrossRef
104.
Yoon M, Schroeter JD, Nong A, Taylor MD, Dorman DC, Andersen ME, et al. Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. Toxicol Sci. 2011;122:297–316.PubMedCrossRef
105.
Verner M-A, Loccisano AE, Morken N-H, Yoon M, Wu H, McDougall R, et al. Associations of perfluoroalkyl substances (PFAS) with lower birth weight: an evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). Environ Health Perspect. 2015;123(12):1317–24.PubMedPubMedCentralCrossRef
106.
De Sousa Mendes M, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, et al. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol. 2016;81:646–57.CrossRef
107.
De Sousa Mendes M, Lui G, Zheng Y, Pressiat C, Hirt D, Valade E, et al. A physiologically-based pharmacokinetic model to predict human fetal exposure for a drug metabolized by several CYP450 pathways. Clin Pharmacokinet. 2016; doi:10.​1007/​s40262-016-0457-5 (Epub 2016 Oct 21).
108.
El-Masri H, Kleinstreuer N, Hines RN, Adams L, Tal T, Isaacs K, et al. Integration of life-stage physiologically based pharmacokinetic models with adverse outcome pathways and environmental exposure models to screen for environmental hazards. Toxicol Sci. 2016;152(1):230–43. doi:10.​1093/​toxsci/​kfw082.PubMedPubMedCentralCrossRef
109.
110.
111.
Webb D, Buss D, Fifield R, Bateman D, Routledge P. The plasma protein binding of metoclopramide in health and renal disease. Br J Clin Pharmacol. 1986;21(3):334–6.PubMedPubMedCentralCrossRef
112.
Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum α-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit. 2004;26(1):40–3.PubMedCrossRef
Metadata
Title
Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women
Authors
André Dallmann
Ibrahim Ince
Juri Solodenko
Michaela Meyer
Stefan Willmann
Thomas Eissing
Georg Hempel
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 12/2017
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-017-0538-0

Other articles of this Issue 12/2017

Clinical Pharmacokinetics 12/2017 Go to the issue

Original Research Article

Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide

Original Research Article

Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease

Original Research Article

Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance

Original Research Article

Target-Mediated Drug Disposition Pharmacokinetic–Pharmacodynamic Model of Bosentan and Endothelin-1

Systematic Review

Penetration of Vancomycin into the Cerebrospinal Fluid: A Systematic Review

Review Article

Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor